ITGA4 and melanoma: ITGA4 achieved an AUC over 0.5 in 13 cohorts, comparable to MSI.Score, and outperformed in predicting NSCLC (Ruppin2021_PD1_NSCLC) and melanoma (Riaz2017_PD1_Melanoma_Ipi.Prog, Gide2019_PD1_Melanoma) immunotherapy outcomes (Figure 6D).